Dr. Bobeck S. Modjtahedi, MD

Dr. Modjtahedi practices at Kaiser Permanente Baldwin Park Medical Center in Baldwin Park, California, part of Kaiser Permanente.

Dr. Modjtahedi's NPI, 1922235035, was assigned on June 16, 2009. Dr. Modjtahedi graduated from UC Davis School of Medicine in 2009. Dr. Modjtahedi holds California license A114567.

Dr. Modjtahedi's primary practice is Kaiser Permanente Baldwin Park Medical Center, at 1011 Baldwin Park Blvd, Baldwin Park, CA 91706 in Los Angeles County. The practice phone is (626) 851-1011.

Dr. Modjtahedi's primary practice is Kaiser Permanente Baldwin Park Medical Center in Baldwin Park, California, part of Kaiser Permanente. The medical group on file is Southern California Permanente Medical Group. Dmand AI also links Dr. Modjtahedi to 3 more medical groups and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Modjtahedi practices, 2 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Modjtahedi's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Modjtahedi is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Modjtahedi's licenses on file in 5 states: California, Colorado, Hawaii, Georgia and Massachusetts.

Dmand AI lists cataract and visual impairment and blindness among the conditions Dr. Modjtahedi treats.

CMS data shows 22 Medicare services from Dr. Modjtahedi across 1 procedure code in 2017, for 18 Medicare patients. Medicare paid $1,359 for them. Every service was in an office.

CMS counts 18 Medicare patients who saw Dr. Modjtahedi in 2024. 75% of them have diabetes, and 75% have high blood pressure. Their average risk score is 3.27, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Modjtahedi's median patient age at 65, with 54% women.

In 2024, Dr. Modjtahedi wrote 501 Medicare Part D claims for 108 patients. 77% of them were for generic drugs. CMS names the drug for 453 of them, across 9 drugs with 11 or more claims each, at $12,428 in total drug cost. In 2023, CMS named 441 claims across 9 drugs.

Dr. Modjtahedi accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 70 papers to Dr. Modjtahedi, published from 2007 to 2025. 2018 was the busiest year, with 7. The most frequent topics are Tomography, Optical Coherence, Diabetic Retinopathy and Visual Acuity. Dr. Modjtahedi has published most often in JAMA Ophthalmol. Dr. Modjtahedi's most frequent co-authors are Donald S. Fong, MD, Nazanin Ebrahimiadib, MD and Donald Fong, MD.

CMS Open Payments shows 6 general payments to Dr. Modjtahedi from 5 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. Allergan Inc. paid the most, $221.

Dr. Modjtahedi graduated from UC Davis School of Medicine in 2009.

Dr. Modjtahedi is in network with 3 carriers, including Kaiser Permanente, CMS Medicare and GA State Medicaid. EPO plans come from the most carriers, 1. Check the plan with the practice before a visit.